Indivior (INDV)
(Delayed Data from NSDQ)
$9.68 USD
-0.34 (-3.39%)
Updated Sep 10, 2024 04:00 PM ET
After-Market: $9.68 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth A Momentum B VGM
Price, Consensus and EPS Surprise
INDV 9.68 -0.34(-3.39%)
Will INDV be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for INDV based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for INDV
Addex Stock Soars on Crucial Update From Indivior Research Deal
Indivior PLC (INDV) Q2 Earnings and Revenues Beat Estimates
INDV: What are Zacks experts saying now?
Zacks Private Portfolio Services
Analysts Estimate Stevanato Group (STVN) to Report a Decline in Earnings: What to Look Out for
Analysts Estimate Indivior PLC (INDV) to Report a Decline in Earnings: What to Look Out for
New Strong Sell Stocks for July 12th
Other News for INDV
Deutsche Bank Sticks to Their Buy Rating for Indivior (INDV)
French Biotech Candidate For Cannabis Use Disorder Fails Phase 2B Clinical Trial, Indivior Will Not Exercise Option
Indivior reports "disappointing" results for study with Aelis Farma
Craig-Hallum Keeps Their Buy Rating on Indivior (INDV)
Indivior provides update on AEF01171 trial, does not expect to exercise option